US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Amicus Therapeutics, Inc. - Common Stock (NQ:FOLD)

14.49 UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amicus Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Shareholders to Contact the Firm
From Kaskela Law LLC
Via Business Wire
News headline image
Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For February 19, 2025 ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Amicus Therapeutics Through 6 Analysts ↗
 
Via Benzinga
News headline image
A Closer Look at 8 Analyst Recommendations For Amicus Therapeutics ↗
 
Via Benzinga
News headline image
Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium™ 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
The Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 Experts ↗
 
Via Benzinga
News headline image
Amicus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (8 Ratings) ↗
 
Via Benzinga
News headline image
Peeling Back The Layers: Exploring Amicus Therapeutics Through Analyst Insights ↗
 
Via Benzinga
News headline image
Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? ↗
Morgan Stanley downgrades Amicus Therapeutics, Immunocore, and Immuneering, citing pricing challenges, pipeline updates, and cautious growth outlooks. 
Via Benzinga
News headline image
Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Expert Outlook: Amicus Therapeutics Through The Eyes Of 4 Analysts ↗
 
Via Benzinga
News headline image
Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug ↗
Amicus Therapeutics enters a license agreement with Teva Pharmaceuticals resolving patent litigation over a generic version of Galafold. Teva may market its version starting in 2037, pending FDA... 
Via Benzinga
Topics Intellectual Property Lawsuit
News headline image
Travelers Posts Upbeat Results, Joins Iridium Communications, Snap-on And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva
Company Grants Teva a License to Market Generic Galafold® Beginning in January 2037 
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Announces Participation at the World Muscle Society Annual Congress 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Investors to Contact the Firm
From Kaskela Law LLC
Via Business Wire
News headline image
UPDATE -- Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Announces Participation at the SSIEM 2024 Annual Symposium
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗
FOLD stock results show that Amicus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Amicus Therapeutics Announces Second Quarter 2024 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >